Rimegepant shows promise in acute migraine attacks

September 6, 2019 0 By FM

Richard B. Lipton et al found that the drug rimegepant could eliminate pain and bothersome symptoms on treating patients with migraine in a large-scale phase 3 trial. Rimegepant is an oral calcitonin gene-related peptide receptor antagonist. Researchers randomly assigned adults with at least a 1-year history of migraine and two to eight migraine attacks of moderate or severe intensity per month to receive rimegepant orally at a dose of 75 mg or matching placebo for the treatment of a single migraine attack. Of a total 1186 patients involved in the study, 594 patients received rimegepant while 592 patients were subjected to placebo treatment. About 88.7% of the candidates were women. The percentage of patients who were
pain-free 2 hours after receiving the dose was 19.6% in the rimegepant group and 12.0% in the placebo group. The percentage of patients who were free from their most bothersome symptom 2 hours after the dose was 37.6% in the rimegepant group and 25.2% in the placebo group. The results confirm rimegepant mechanism of action—blocking the CGRP pathway—effectively relieves pain and associated symptoms that occur during acute migraine
attacks.